The goals of the Forum will be to:

•Identify a rational strategy to selecting specific approaches to target GD2;

•Define a strategy for the further development of monoclonal antibodies;

•Define a strategy to develop and evaluate new products;

•Identify and prioritise most promising  new medicinal products;

•Highlight the importance of diagnostics for GD2 expression and HACA and HAHA.

Format: This forum will be held in person and all participants are strongly encouraged to attend it. For attendees unable to travel or if travel restrictions prevent an in-person event, a virtual option will be available.   

Forum Output: Publication of a summary and manuscript from all participants addressing the challenges and documenting the conclusions of the meeting. Potentially further specific meetings relating to areas which require more in-depth discussion will be arranged.

Participation: Possible only by invitation or by submitting an Expression of Interest (see below) before the 30 June 2024. 

Submit your Expression of Interest: The call for expressions of interest is open now – please use the box available below. Invitations will be sent out by the end of July 2024.